Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DM1001
- Development stage
- Phase 1
- Lead developer
- Wanbang Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
DM1001 is a long-acting, once-weekly injectable formulation of pramipexole, a non-ergoline dopamine agonist. Developed by Nanjing Jicui Jiding Pharmaceutical (Jiding Pharma) in collaboration with Fosun Wanbang, it is intended for the treatment of signs and symptoms of idiopathic Parkinson's disease. The drug utilizes a proprietary delivery technology to provide sustained release of pramipexole, aiming to improve patient compliance and provide more stable plasma concentrations compared to standard daily oral formulations. It primarily acts as a potent agonist at the dopamine D2 and D3 receptor subtypes to alleviate motor symptoms associated with Parkinson's disease.
- Other names
- weekly pramipexolepramipexole long-acting injection
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on DM1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DM1001.